Nuvectis Pharma, Inc.
HealthcareNASDAQ:NVCT · NASDAQ Capital Market
+$0.20 today
Vol 0.07M · Avg 0.08M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$27.2M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.31, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $725.6M | $804.0M | $882.4M |
| Gross Profit | $0 | $0 | $0 | $0 | $0 | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | — | 9.8% | 28.9% | 38.3% |
| Research & Development | $18.2M +40.5% | $12.9M -16.0% | $15.4M +16.3% | $13.2M +38.6% | $9.5M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $9.4M +36.0% | $6.9M -7.8% | $7.5M +25.1% | $6.0M +79.4% | $3.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $27.6M +38.9% | $19.8M -13.3% | $22.9M +19.0% | $19.2M +49.2% | $12.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $0 | $0 | $0 | $0 | $0 | $374.2M | $1.2B | $631.8M |
| EBITDA | -$26.4M -39.2% | -$19.0M +14.6% | -$22.3M -16.6% | -$19.1M -48.1% | -$12.9M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | — | 5.6% | 46.3% | 42.0% |
| Operating Income | -$27.6M -38.9% | -$19.8M +13.3% | -$22.9M -19.0% | -$19.2M -49.2% | -$12.9M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | — | 16.6% | 24.1% | 22.0% |
| Interest Income | $1.1M +33.6% | $847.0K +33.0% | $637.0K +327.5% | $149.0K +3625.0% | $4.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 | $0 | $0 | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $1.1M +33.6% | $847.0K +33.0% | $637.0K +327.5% | $149.0K +3625.0% | $4.0K | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$26.4M -39.2% | -$19.0M +14.6% | -$22.3M -16.6% | -$19.1M -48.1% | -$12.9M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | — | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$26.4M -39.2% | -$19.0M +14.6% | -$22.3M -16.6% | -$19.1M -48.1% | -$12.9M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | — | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$1 -18.9% | -$1 +22.4% | -$1 +5.3% | -$2 -38.5% | -$1 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$1 -18.9% | -$1 +22.4% | -$1 +5.3% | -$2 -38.5% | -$1 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $21.8M +27.5% | $17.1M +10.0% | $15.6M +22.9% | $12.7M -0.5% | $12.7M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $21.8M +27.5% | $17.1M +10.0% | $15.6M +22.9% | $12.7M -0.5% | $12.7M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Cybin Inc.
CYBN
$413.02M
Armata Pharmaceuticals, Inc.
AMEX:ARMP
$278.27M
Compugen Ltd.
NASDAQ:CGEN
$192.89M
Tonix Pharmaceuticals Holding Corp.
NASDAQ:TNXP
$180.93M
Innate Pharma S.A.
NASDAQ:IPHA
$165.27M
Molecular Partners AG
NASDAQ:MOLN
$154.17M
Milestone Pharmaceuticals Inc.
NASDAQ:MIST
$109.08M
Cardiff Oncology, Inc.
NASDAQ:CRDF
$105.29M
Cassava Sciences, Inc.
SAVA
$63.77M
Rani Therapeutics Holdings, Inc.
NASDAQ:RANI
$49.65M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does NVCT generate?
Nuvectis Pharma, Inc. (NVCT) reported $0.00 of revenue in fiscal 2025.
Is NVCT profitable?
Nuvectis Pharma, Inc. (NVCT) reported -$26,442,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.